Cedar Brook Financial Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cedar Brook Financial Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,282	Closed	-$217K	–	426
2024 Q1	$217K	Hold	2,282	–	–	0.04%	404
2023 Q4	$206K	Buy	+2,282	New	+$169K	0.05%	390
2022 Q4	–	Sell	-4,318	Closed	-$343K	–	393
2022 Q3	$343K	Buy	4,318 +52	+1%	+$4.38K	0.11%	215
2022 Q2	$317K	Sell	4,266 -3,981	-48%	-$299K	0.1%	232
2022 Q1	$741K	Buy	8,247 +1,531	+23%	+$141K	0.19%	137
2021 Q4	$752K	Buy	+6,716	New	+$810K	0.19%	126
2021 Q1	–	Sell	-2,178	Closed	-$307K	–	352
2020 Q4	$307K	Buy	+2,178	New	+$279K	0.11%	210

Other funds holding XBI

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Cedar Brook Financial Partners's XBI Position: Q2 2024 in Review

Cedar Brook Financial Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 2,282 shares — an estimated $217K sold.

Cedar Brook Financial Partners first reported a position in XBI in Q4 2020 and held it in 7 quarters. The position peaked at $752K in Q4 2021. 762 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Cedar Brook Financial Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Cedar Brook Financial Partners sold 2,282 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $217K.
Cedar Brook Financial Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 7 quarters.
Cedar Brook Financial Partners's State Street SPDR S&P Biotech ETF position peaked at $752K in Q4 2021.
762 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Cedar Brook Financial Partners's 13F filing for Q2 2024, filed 15 Jul 2024.